The Role of COX-1 and COX-2 in Alzheimer's Disease Pathology and the Therapeutic Potentials of Non-Steroidal Anti-Inflammatory Drugs

Authors: Hoozemans, Jeroen J.M.; O'Banion, M. K.

Source: Current Drug Targets-CNS & Neurological Disorders, Volume 4, Number 3, June 2005 , pp. 307-315(9)

Publisher: Bentham Science Publishers

Abstract:

Epidemiological studies indicate that anti-inflammatory drugs, especially the non-steroidal antiinflammatory drugs (NSAIDs), decrease the risk of developing Alzheimer's disease (AD). Their beneficial effects may be due to interference of the chronic inflammatory reaction in AD. The best-characterised action of NSAIDs is the inhibition of cyclooxygenase (COX). So far, clinical trials designed to inhibit inflammation or cyclooxygenase activity have failed in the treatment of AD patients. In this review we will focus on the role, expression and regulation of COX-1 and COX-2 in neurodegeneration and AD pathogenesis. Understanding the pathological, physiological and neuroprotective role of cyclooxygenase will contribute to the development of a therapy for the treatment or prevention of AD.

Keywords: alzheimers disease; cox; neuroinflammation; microglia; neuron; nsaids

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1568007054038201

Affiliations: 1: Academic Medical Center, Neurogenetics Laboratory, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands.

Publication date: 2005-06-01

More about this publication?

• CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will contain a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in neurological and CNS disorders. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.

Related content

• In this: publication
• By this: publisher
• In this Subject: Neurology & Psychiatry ,  Pharmacology
• By this author: Hoozemans, Jeroen J.M. ;  O'Banion, M. K.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers